EP Patent

EP1176141A4 — HETEROCYCLIC COMPOUNDS HAVING RECEPTOR ACTIVATION EFFECT $ g (a) 4 $ g (b) 2 OF NICOTINIC ACETYLCHOLINE

Assigned to Asubio Pharma Co Ltd · Expires 2002-08-14 · 24y expired

What this patent protects

Heterocyclic compounds showing an affinity for nicotinic acetylcholine α4β2 receptor and activating the same to thereby exert a preventive or therapeutic effect on brain diseases. Namely, nicotinic acetlycholine α4β2 receptor activators comprising, as the active ingredient, compo…

USPTO Abstract

Heterocyclic compounds showing an affinity for nicotinic acetylcholine α4β2 receptor and activating the same to thereby exert a preventive or therapeutic effect on brain diseases. Namely, nicotinic acetlycholine α4β2 receptor activators comprising, as the active ingredient, compounds represented by general formula (I) or pharmacologically acceptable salts thereof and drugs containing the same: wherein A represents optionally substituted aryl or an optionally subsituted heterocycle; X represents oxygen, sulfur, carbon or nitrogen; dotted lines represent each the presence or absence of a bond; n is an integer of 1 or 2; and Y represents alkylene, etc.

Drugs covered by this patent

Patent Metadata

Patent number
EP1176141A4
Jurisdiction
EP
Classification
Expires
2002-08-14
Drug substance claim
No
Drug product claim
No
Assignee
Asubio Pharma Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.